Objectives: Survival in head and neck squamous cell carcinoma (HNSCC) has been associated with patient sex, typically with males experiencing poorer outcomes. It is unclear if this disparity is based in divergent tumor biology. We analyzed the TCGA HNSCC cohort to uncover disparities in the somatic single nucleotide variation (SNV), copy number alteration (CNA) and mRNA abundance profiles between males and females. Critically, we stratified our results by tumor HPV status to control for this significant confounder.
Methods: SNV, CNA and mRNA abundance differences between males and females were compared separately for the HPV-positive (n = 67) and negative (n = 431) TCGA HNSCC cohorts. Overall survival outcomes were compared in males and females in both HPV-positive and HPV-negative subsets of patients.
Results: Females were found to have poorer overall survival than males (p = 0.048), largely due to higher rates of HPV-positive disease among men. SNV analysis revealed that in HPV-positive disease, there were no differences by sex after accounting for the false discovery rate (FDR). In HPV-negative tumors, BRWD3 mutations occurred more frequently in the tumors of female patients compared to males after adjusting for the FDR (p = 0.02). Further, HPV-negative BRWD3 mutant tumors were found to have significantly worse 5-year overall survival compared to wildtype on multivariate analysis (p = 0.02). There were 88 heterozygous deletions and 14 amplifications that were differentially altered between male and female HPV-negative tumors and associated with expression changes. Pathway analysis of these genes revealed that tumors from males were enriched in five pathways including chemokine and phosphophatidylinositol signaling.
Conclusions: Reanalysis of the TCGA HNSCC dataset stratified by sex revealed that males in this cohort had a significant survival advantage, due to a higher proportion of HPV-positive disease. Mutations in BRWD3 were more frequent in HPV-negative tumors of females and were associated with poorer overall survival. BRWD3 may represent a novel biomarker of patient outcomes, but will require additional validation.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status.JCI Insight. 2019 Jan 10;4(1):e123443. doi: 10.1172/jci.insight.123443. Online ahead of print. JCI Insight. 2019. PMID: 30626742 Free PMC article.
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.Clin Cancer Res. 2015 Feb 1;21(3):632-41. doi: 10.1158/1078-0432.CCR-13-3310. Epub 2014 Jul 23. Clin Cancer Res. 2015. PMID: 25056374 Free PMC article.
NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents.Cancers Head Neck. 2019 Jul 8;4:3. doi: 10.1186/s41199-019-0042-3. eCollection 2019. Cancers Head Neck. 2019. PMID: 31321084 Free PMC article.
Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.Oral Oncol. 2016 Aug;59:58-66. doi: 10.1016/j.oraloncology.2016.05.014. Oral Oncol. 2016. PMID: 27424183 Free PMC article. Review.
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240. doi: 10.1016/j.semcancer.2018.01.008. Epub 2018 Jan 31. Semin Cancer Biol. 2018. PMID: 29355614 Review.